Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane.

Tytuł:
STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane.
Autorzy:
Heo W; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Jin N; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Park MS; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Kim HY; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Yoon SM; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea.
Lee J; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea.
Kim JY; Department of Pharmacology and Brain, Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Źródło:
Clinical and experimental immunology [Clin Exp Immunol] 2020 Jun; Vol. 200 (3), pp. 260-271. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2022- : Oxford : Oxford University Press
Original Publication: Oxford : Blackwell Scientific Publications
MeSH Terms:
Gene Knockdown Techniques*
Antibodies, Monoclonal, Humanized/*immunology
Antigens, CD20/*immunology
Cell Membrane/*immunology
Neoplasm Proteins/*immunology
Stromal Interaction Molecule 1/*immunology
Animals ; Antigens, CD20/genetics ; CHO Cells ; Cell Membrane/genetics ; Cricetulus ; Humans ; Neoplasm Proteins/genetics ; Octoxynol/chemistry ; Solubility ; Stromal Interaction Molecule 1/genetics
References:
J Biol Chem. 2004 May 7;279(19):19893-901. (PMID: 14976189)
J Biol Chem. 2015 Feb 27;290(9):5424-37. (PMID: 25568316)
J Biol Chem. 2003 Oct 24;278(43):42427-34. (PMID: 12920111)
J Immunol. 1988 Dec 15;141(12):4388-94. (PMID: 2461992)
Semin Hematol. 2010 Apr;47(2):107-14. (PMID: 20350657)
Oncogene. 2003 Oct 20;22(47):7359-68. (PMID: 14576843)
Annu Rev Biochem. 2017 Jun 20;86:659-684. (PMID: 28301744)
Blood. 2014 Oct 2;124(14):2196-202. (PMID: 25143487)
Mol Immunol. 2007 Sep;44(16):3823-37. (PMID: 17768100)
Blood. 2011 Jul 14;118(2):358-67. (PMID: 21444918)
Blood. 2011 Apr 28;117(17):4519-29. (PMID: 21378274)
Leuk Lymphoma. 2013 Nov;54(11):2500-5. (PMID: 23452151)
Cancer Res. 2003 Sep 1;63(17):5480-9. (PMID: 14500384)
J Biol Chem. 2008 Jul 4;283(27):18545-52. (PMID: 18474602)
Mol Cancer Ther. 2013 Oct;12(10):2031-42. (PMID: 23873847)
Immunol Res. 2014 Aug;59(1-3):203-10. (PMID: 24906530)
Blood. 1998 Mar 1;91(5):1644-52. (PMID: 9473230)
Blood. 2010 Jun 3;115(22):4393-402. (PMID: 20194898)
J Biol Chem. 2008 Jun 20;283(25):17333-40. (PMID: 18430726)
J Clin Oncol. 2013 Aug 10;31(23):2920-6. (PMID: 23835715)
Blood. 1994 Jan 15;83(2):435-45. (PMID: 7506951)
Br J Haematol. 2008 Jul;142(3):394-403. (PMID: 18544085)
Clin Exp Immunol. 2005 Mar;139(3):439-46. (PMID: 15730389)
Nat Struct Mol Biol. 2013 Aug;20(8):973-81. (PMID: 23851458)
J Immunol. 1998 Oct 1;161(7):3242-8. (PMID: 9759838)
J Cell Biol. 2005 May 9;169(3):435-45. (PMID: 15866891)
Curr Biol. 2005 Jul 12;15(13):1235-41. (PMID: 16005298)
N Engl J Med. 2017 Oct 5;377(14):1331-1344. (PMID: 28976863)
Blood. 2011 Nov 10;118(19):5178-88. (PMID: 21948297)
J Immunol. 2015 Sep 1;195(5):2207-15. (PMID: 26202984)
MAbs. 2013 Jan-Feb;5(1):22-33. (PMID: 23211638)
J Cell Biol. 1993 Jun;121(5):1121-32. (PMID: 7684739)
Nat Commun. 2014 Dec 17;5:5843. (PMID: 25517631)
J Biol Chem. 2008 Jun 20;283(25):16971-84. (PMID: 18426802)
Nat Rev Clin Oncol. 2019 Feb;16(2):65. (PMID: 30575810)
Cancers (Basel). 2019 Mar 01;11(3):. (PMID: 30832225)
Contributed Indexing:
Keywords: CD20; Ca2+; STIM1; direct binding-induced cell death; obinutuzumab; raft
Substance Nomenclature:
0 (Antibodies, Monoclonal, Humanized)
0 (Antigens, CD20)
0 (Neoplasm Proteins)
0 (STIM1 protein, human)
0 (Stromal Interaction Molecule 1)
9002-93-1 (Octoxynol)
O43472U9X8 (obinutuzumab)
Entry Date(s):
Date Created: 20200215 Date Completed: 20201013 Latest Revision: 20210602
Update Code:
20240105
PubMed Central ID:
PMC7232002
DOI:
10.1111/cei.13427
PMID:
32056202
Czasopismo naukowe
Obinutuzumab is thought to exert its effects through its high antibody-dependent cellular cytotoxicity (ADCC) via glyco-engineering of the Fc region. In addition, obinutuzumab causes direct binding-induced cell death (DCD) only by specifically binding to its target CD20, a Ca 2+ channel. However, the specific features of CD20 related to obinutuzumab binding-induction of cell death are not clearly understood. In this study, we evaluated the relationship between the Ca 2+ channel features of CD20 as a store-operated Ca 2+ channel (SOC) and obinutuzumab binding-induced cell death. Ca 2+ channel function and biochemical analysis revealed that CD20 is an Orai1- and stromal interaction molecule (STIM1)-dependent Ca 2+ pore. However, binding of obinutuzumab on CD20 did not have any effect on Ca 2+ influx activity of CD20; the direct cell death rate mediated by obinutuzumab binding was almost equivalent with or without the extracellular Ca 2+ condition. Given the apparent interaction between STIM1 and CD20, we observed Triton-X solubilized obinutuzumab-bound CD20 accompanied by STIM1. Subsequently, obinutuzumab binding and cell death were decreased by STIM1 knock-down in Ramos B cells. Thus, STIM1 directly contributes to cell death by increasing the affinity of cells for obinutuzumab by transferring CD20 to the Triton-soluble membrane region.
(© 2020 British Society for Immunology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies